TY - JOUR AU - Ghasemnejad-Berenji, Morteza; Pashapour, Sarvin TI - Favipiravir and COVID-19: A Simplified Summary SN - 2194-9379 SN - 2194-9387 PY - 2020 JO - Drug Res (Stuttg) JF - Drug Research LA - EN VL - 71 IS - 03 SP - 166 EP - 170 DA - 2020/11/11 KW - antiviral drugs KW - drug research KW - clinical trials AB - A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan, China, at the end of 2019 and then spread rapidly all over the world. However, there are no specific antiviral therapies for COVID-19, using the agents which approved or in development for other viral infections is one of the potentially quickest ways to find treatment for this new viral infection. Favipiravir is an effective agent that acts as a nucleotide analog that selectively inhibits the viral RNA dependent RNA polymerase or causes lethal mutagenesis upon incorporation into the virus RNA. In view of recent studies and discussion on favipiravir, in this mini review we aimed to summarize the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19. PB - Georg Thieme Verlag KG DO - 10.1055/a-1296-7935 UR - http://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1296-7935 ER -